Contrasting effects of LSD1 and DOT1L inhibition on chromatin accessibility. (A-C) Composite plots show normalized ATAC-seq signal at all dynamic sites in treatment and control for GSK-LSD1 in mouse (A) and PDX (B) and for EPZ4777 in mouse (C). (D-F) ATAC-seq peak dynamics in treatment and control for GSK-LSD1 in mouse (D) and PDX (E) and for EPZ4777 in mouse (F). (G) Heat map of normalized ATAC-seq read density at sites ranked by gain with GSK-LSD1 treatment, and the corresponding sites under control and EPZ4777 treatment. (H) Heat map of normalized ATAC-seq read density at sites ranked by loss with EPZ4777 treatment, and the corresponding sites under control and GSK-LSD1 treatment. (I) Venn diagram showing the overlap between dynamic ATAC-seq sites under treatment GSK-LSD1 or EPZ4777 relative to control. (J) Genome annotation of dynamic ATAC-seq sites under treatment GSK-LSD1 or EPZ4777 relative to control. ctrl, control.